查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649460

神經系統疾病診斷與治療市場預測（2025-2030）

Neurological Disorder Diagnostics Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

神經系統疾病診斷和治療市場預計將以 5.68% 的複合年成長率成長，從 2025 年的 143.4 億美元成長到 2030 年的 189.03 億美元。

神經系統疾病是一種影響神經系統功能的疾病，包括大腦、脊髓和神經。這些病症包括多種疾病，包括阿茲海默症和帕金森氏症等神經退化性疾病、肌肉萎縮症營養不良症和肌肉萎縮側索硬化症等神經肌肉疾病、脊柱裂和脊髓神經病變等脊椎疾病，以及周邊神經病變和腕隧道症候群等周邊神經問題。神經系統疾病診斷市場包括診斷這些疾病所使用的所有工具、技術、設備、產品和服務。這包括磁振造影（MRI）、電腦斷層掃描（CT）、神經影像生物標記、超音波系統、血液和腦脊髓液生物標記檢測、基因檢測和用於資料分析的穿戴式設備等技術。有幾個因素推動了神經疾病診斷市場的成長。這在很大程度上是由於阿茲海默症、失智症和帕金森氏症等神經系統疾病的發生率不斷上升。此外，事故造成腦損傷的增加進一步刺激了市場需求。政府、非政府組織和機構為提高人們對早期篩檢神經系統健康重要性的認知而做出的努力也推動了早期診斷的需求。此外，研發投入的增加也推動了診斷技術和流程的進步。人工智慧（AI）和機器學習技術的日益普及也透過提供更準確的資料分析推動了市場成長。此外，各國政府（特別是新興國家）增加對醫療保健的投資，也進一步支持了市場擴張。

神經疾病診斷市場促進因素：

  • 神經系統疾病發生率上升：全球神經系統疾病發病率上升是由多種因素造成的，包括以壓力為特徵的生活方式的改變、心理健康問題、身體活動減少、對數位科技的依賴、人口老化和環境污染。這些因素導致阿茲海默症和帕金森氏症等疾病的發病率迅速上升，增加了對診斷工具和技術的需求。根據阿茲海默症協會的資料，約有480萬65歲及以上的美國阿茲海默症而患有失智症，美國失智症患者總合690萬人。

影響神經診斷市場的地理趨勢：

  • 亞太地區快速成長：神經疾病診斷市場分為北美、南美、歐洲、中東和非洲、亞太等地區。預計預測期內亞太地區將成為該市場成長最快的地區。這一成長主要由中國、韓國和印度等新興國家推動，這些國家正在加強醫療保健基礎設施，以應對日益成長的神經系統疾病發病率。

例如，預計2022年中國將有約480萬新發癌症病例，257萬人死於癌症。這凸顯了透過先進的診斷技術開發個人化醫療的迫切需求。另一方面，由於北美擁有先進的醫療保健基礎設施，預計將佔據神經系統疾病診斷市場的大部分佔有率。神經系統疾病的高發生率也促成了這個優勢。預計到2024年，阿茲海默症導致失智症的人數將達到690萬人。總而言之，神經診斷市場正在經歷強勁成長，其推動力包括全球神經系統疾病患病率上升、人們對早期診斷認知的不斷提高、診斷工具和流程的技術進步、政府在醫療保健投資方面的支持性舉措以及有利的市場趨勢（尤其是在亞太地區），這些都在強化不斷擴大的市場環境。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 細分和區域分析，包括收益成長和預測國家
  • 公司概況（策略、產品、財務、主要發展等）

神經診斷和治療市場細分如下：

依疾病類型

  • 神經退化性疾病
  • 神經肌肉疾病
  • 脊椎疾病
  • 周邊神經疾病

依技術分類

  • 診斷影像技術
  • 體外診斷技術

按最終用戶

  • 醫院和診所
  • 診斷中心
  • 其他

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 其他
  • 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 其他
  • 亞太地區
  • 中國
  • 日本
  • 韓國
  • 澳洲
  • 印度
  • 印尼
  • 泰國
  • 其他

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章 神經系統疾病診療市場（依疾病類型）

  • 介紹
  • 神經退化性疾病
  • 神經肌肉疾病
  • 脊椎疾病
  • 周邊神經病變

第6章 神經系統疾病診斷與治療市場（依技術）

  • 介紹
  • 成像技術
  • 體外診斷技術

第7章 神經系統疾病診斷與治療市場（依最終使用者）

  • 介紹
  • 醫院和診所
  • 診斷中心
  • 其他

第8章 神經系統疾病診療市場區域分佈

  • 介紹
  • 北美洲
    • 依疾病類型
    • 依技術分類
    • 按最終用戶
    • 按國家
  • 南美洲
    • 依疾病類型
    • 依技術分類
    • 按最終用戶
    • 按國家
  • 歐洲
    • 依疾病類型
    • 依技術分類
    • 按最終用戶
    • 按國家
  • 中東和非洲
    • 依疾病類型
    • 依技術分類
    • 按最終用戶
    • 按國家
  • 亞太地區
    • 依疾病類型
    • 依技術分類
    • 按最終用戶
    • 按國家

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • GE Healthcare
  • Siemens Healthcare
  • FUJIFILM Holdings Corporation
  • Koninklijke Philips NV
  • Thermo Fisher Scientific Inc.
  • Masimo
  • Medtronic
  • Abbott Laboratories
簡介目錄
Product Code: KSI061617236

The neurological disorder diagnostics treatment market is expected to grow at a CAGR of 5.68%, reaching a market size of US$18.903 billion in 2030 from US$14.340 billion in 2025

Neurological disorders are conditions that impact the functioning of the nervous system, including the brain, spinal cord, and nerves. These disorders encompass a range of conditions, such as neurodegenerative diseases like Alzheimer's and Parkinson's disease, neuromuscular disorders like muscular dystrophy and amyotrophic lateral sclerosis, spine conditions such as spina bifida and spinal cord injuries, as well as peripheral nerve issues like peripheral neuropathy and carpal tunnel syndrome.The neurological disorder diagnostics market includes all tools, techniques, devices, products, and services used to diagnose these conditions. This encompasses technologies such as magnetic resonance imaging (MRI), computed tomography (CT), neuroimaging biomarkers, ultrasound systems, blood and cerebrospinal fluid tests for biomarkers, genetic testing, and wearable devices for data analysis. Key settings for these diagnostics include hospitals, clinics, and diagnostic centers.Several factors are driving the growth of the neurological disorder diagnostics market. The rising prevalence of neurological diseases such as Alzheimer's, dementia, and Parkinson's disease is a significant contributor. Additionally, the increasing number of brain injuries due to accidents further boosts market demand. Efforts by governments, NGOs, and institutions to raise awareness about the importance of early screening for neurological health are also propelling demand for early diagnosis. Furthermore, increased investment in research and development has led to advancements in diagnostic technologies and processes. The growing adoption of artificial intelligence (AI) and machine learning technologies enhances market growth by providing more accurate data analysis. Additionally, rising healthcare investments by governments-particularly in emerging countries-are further fueling market expansion.

Drivers of the Neurological Disorder Diagnostics Market:

  • Rising Prevalence of Neurological Disorders: The global increase in neurological disorders is driven by various factors including lifestyle changes characterized by stress, mental health issues, reduced physical activity, reliance on digital technology, an aging population, and environmental pollution. These factors contribute to a surge in diseases like Alzheimer's and Parkinson's disease, thereby increasing the demand for diagnostic tools and techniques. According to data from the Alzheimer's Association, approximately 4.8 million Americans aged 65 and older have dementia due to Alzheimer's disease, with a total of 6.9 million individuals affected by dementia in the U.S.

Geographical Trends Shaping the Neurological Disorder Diagnostics Market:

  • Rapid Growth in Asia-Pacific: The neurological disorder diagnostics market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is anticipated to be the fastest-growing region in this market. This growth is driven by emerging economies such as China, South Korea, and India, which are enhancing their healthcare infrastructure to address the increasing prevalence of neurological disorders.

For instance, it was estimated that around 4.8 million new cancer cases and 2.57 million cancer deaths occurred in China in 2022. This highlights the critical need for personalized medicine development through advanced diagnostic technologies.Meanwhile, North America is expected to maintain a significant share of the neurological disorder diagnostics market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this dominance; projections indicate that there will be 6.9 million dementia patients due to Alzheimer's in 2024. Additionally, government investments and private sector initiatives are driving continued regional expansion.In summary, the neurological disorder diagnostics market is experiencing robust growth driven by rising prevalence of neurological disorders globally, increased awareness about early diagnosis, technological advancements in diagnostic tools and processes, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Neurological Disorder Diagnostics Treatment Market has been segmented as following:

By Type of Disorder

  • Neurodegenerative Disorders
  • Neuromuscular Disorders
  • Spinal Disorders
  • Peripheral Nerve Disorder

By Technology

  • Imaging Techniques
  • In Vitro Diagnostic Techniques

By End-User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TYPE OF DISORDER

  • 5.1. Introduction
  • 5.2. Neurodegenerative Disorders
  • 5.3. Neuromuscular Disorders
  • 5.4. Spinal Disorders
  • 5.5. Peripheral Nerve Disorder

6. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Imaging Techniques
  • 6.3. In Vitro Diagnostic Techniques

7. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostic Centers
  • 7.4. Others

8. NEUROLOGICAL DISORDER DIAGNOSTICS TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type of Disorder
    • 8.2.2. By Technology
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type of Disorder
    • 8.3.2. By Technology
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type of Disorder
    • 8.4.2. By Technology
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type of Disorder
    • 8.5.2. By Technology
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type of Disorder
    • 8.6.2. By Technology
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. Australia
      • 8.6.4.5. India
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Thailand
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. GE Healthcare
  • 10.2. Siemens Healthcare
  • 10.3. FUJIFILM Holdings Corporation
  • 10.4. Koninklijke Philips N.V.
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Masimo
  • 10.7. Medtronic
  • 10.8. Abbott Laboratories